Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cardiotoxicity × dapagliflozin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Solid Tumors 1 Prostatic Neoplasms 1 Inflammation 1 Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Heart Failure 1 Cardiotoxicity 1

Interventions

Doxorubicin 7 Cyclophosphamide 4 Docetaxel 3 Atorvastatin 3 Trastuzumab 2 Chemotherapy, Adjuvant 2 Carvedilol 2 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 Tablets 1 Reverse Transcriptase Polymerase Chain Reaction 1 Radiotherapy 1 Paclitaxel 1 Neoadjuvant Therapy 1 Methotrexate 1 Mass Spectrometry 1 Lisinopril 1 Leucovorin 1 Lapatinib 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Gene Expression Profiling 1 Fluorophotometry 1 Filgrastim 1 Fenofibrate 1 Epirubicin 1 Environmental Biomarkers 1 Echocardiography 1 Dexrazoxane 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06341842 2024-04-02

PROTECT

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Recruiting

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡